Literature DB >> 24232915

Understanding internalization of rotavirus VP6 nanotubes by cells: towards a recombinant vaccine.

Mabel Rodríguez, Christopher Wood, Rosana Sanchez-López, Ricardo M Castro-Acosta, Octavio T Ramírez, Laura A Palomares.   

Abstract

Rotavirus VP6 nanotubes are an attractive option for a recombinant vaccine against rotavirus disease. Protection against rotavirus infection and an adjuvant effect have been observed upon immunization with VP6 nanotubes. However, little information exists on how VP6 nanotubes interact with cells and trigger an immune response. In this work, the interaction between VP6 nanotubes and different cell lines was characterized. VP6 nanotubes were not cytotoxic to any of the animal or human cell lines tested. Uptake of nanotubes into cells was cell-line-dependent, as only THP1 and J774 macrophage cells internalized them. Moreover, the size and spatial arrangement of VP6 assembled into nanotubes allowed their uptake by macrophages, as double-layered rotavirus-like particles also displaying VP6 in their surface were not taken up. The internalization of VP6 nanotubes was inhibited by methyl-β-cyclodextrin, but not by genistein, indicating that nanotube entry is specific, depends on the presence of cholesterol in the plasma membrane, and does not require the activity of tyrosine kinases. The information generated here expands our understanding of the interaction of protein nanotubes with cells, which is useful for the application of VP6 nanotubes as a vaccine.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24232915     DOI: 10.1007/s00705-013-1916-z

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  7 in total

1.  Rotavirus vaccines: why continued investment in research is necessary.

Authors:  Michelle M Arnold
Journal:  Curr Clin Microbiol Rep       Date:  2018-01-18

2.  Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.

Authors:  Vesna Blazevic; Maria Malm; Daisuke Arinobu; Suvi Lappalainen; Timo Vesikari
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

3.  Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.

Authors:  M Malm; S Heinimäki; T Vesikari; V Blazevic
Journal:  Clin Exp Immunol       Date:  2017-05-16       Impact factor: 4.330

Review 4.  Rotavirus VP6: involvement in immunogenicity, adjuvant activity, and use as a vector for heterologous peptides, drug delivery, and production of nano-biomaterials.

Authors:  Zabihollah Shoja; Somayeh Jalilvand; Tayebeh Latifi; Farzin Roohvand
Journal:  Arch Virol       Date:  2022-03-15       Impact factor: 2.685

5.  Effect of metal catalyzed oxidation in recombinant viral protein assemblies.

Authors:  Ricardo M Castro-Acosta; William A Rodríguez-Limas; Brenda Valderrama; Octavio T Ramírez; Laura A Palomares
Journal:  Microb Cell Fact       Date:  2014-02-17       Impact factor: 5.328

6.  Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles.

Authors:  Maria Malm; Kirsi Tamminen; Suvi Lappalainen; Timo Vesikari; Vesna Blazevic
Journal:  J Immunol Res       Date:  2016-09-04       Impact factor: 4.818

7.  Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus-Like Particle Uptake and Presentation by Bone Marrow-Derived Dendritic Cells In Vitro and In Vivo.

Authors:  Kirsi Tamminen; Suvi Heinimäki; Timo Vesikari; Vesna Blazevic
Journal:  J Immunol Res       Date:  2020-01-23       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.